Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in ChinaGlobeNewsWire • 08/23/19
Hutchison China MediTech Ltd (HCM) CEO Christian Hogg on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 07/31/19